Benza, Raymond L., Corris, Paul A., Klinger, James R., Langleben, David, Naeije, Robert, Simonneau, Gerald, Ghofrani, Hossein-Ardeschir, Jansa, Pavel ORCID: 0000-0002-3711-7064, Rosenkranz, Stephan, Scelsi, Laura, Thenappan, Thenappan ORCID: 0000-0002-6210-0467, Raina, Amresh, Meier, Christian, Busse, Dennis and Hoeper, Marius M. (2020). Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. Int. J. Cardiol., 317. S. 188 - 193. CLARE: ELSEVIER IRELAND LTD. ISSN 1874-1754

Full text not available from this repository.

Abstract

Background: RESPITE evaluated patients with pulmonary arterial hypertension and an inadequate response to phosphodiesterase type 5 inhibitors (PDE5i) who switched to riociguat. This post hoc analysis assessed response to this switch in parameters associated with clinical improvement. Methods: RESPITE was a 24-week, uncontrolled pilot study (n = 61). Differences in functional, hemodynamic, and cardiac function parameters, REVEAL risk score (RRS), and biomarkers were compared between responders (free from clinical worsening, World Health Organization functional class I/II, and >= 30 m improvement in 6-min walking distance at Week 24) and non-responders. Results: Of 51 patients (84%) completing RESPITE, 16 (31%) met the responder endpoint. At baseline, there were significant differences between responders and non-responders in N-terminal prohormone of brain natriuretic peptide (NT-proBNP), growth/differentiation factor 15 (GDF-15), and RRS, whereas there were no differences in hemodynamics or cardiac function. At Week 24, responders had significant improvements in pulmonary arterial compliance, pulmonary vascular resistance, and mean pulmonary arterial pressure, while non-responders showed no significant change. Cardiac efficiency and stroke volume index significantly improved irrespective of responder status. Conclusions: NT-proBNP, GDF-15, and RRS were identified as potential predictors of response in patients switching from PDE5i to riociguat. Further prospective controlled studies are needed to confirm the association of these parameters with response. (c) 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Benza, Raymond L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Corris, Paul A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klinger, James R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Langleben, DavidUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Naeije, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Simonneau, GeraldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ghofrani, Hossein-ArdeschirUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jansa, PavelUNSPECIFIEDorcid.org/0000-0002-3711-7064UNSPECIFIED
Rosenkranz, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scelsi, LauraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thenappan, ThenappanUNSPECIFIEDorcid.org/0000-0002-6210-0467UNSPECIFIED
Raina, AmreshUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meier, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Busse, DennisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hoeper, Marius M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-314888
DOI: 10.1016/j.ijcard.2020.05.044
Journal or Publication Title: Int. J. Cardiol.
Volume: 317
Page Range: S. 188 - 193
Date: 2020
Publisher: ELSEVIER IRELAND LTD
Place of Publication: CLARE
ISSN: 1874-1754
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
RISK SCORE CALCULATOR; SOLUBLE SUPPRESSION; DISEASE SEVERITY; PROGNOSTIC VALUE; HEART-FAILURE; PULMONARY; TUMORIGENICITY-2; PREDICTORS; MORBIDITY; IMPACTMultiple languages
Cardiac & Cardiovascular SystemsMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/31488

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item